Status: Recruiting
Zilucoplan for Severe gMG Exacerbations
This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive subcutaneous zilucoplan injections daily for 12 weeks. Participation in the study will last for approximately 18 weeks.
Participants needed: 15
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Miriam FreimerUpdated: Feb 23, 2026Locations: 1
Eligibility criteria
Patient determined to have severe MG exacerbation (e.g. bulbar and/or respirator... [+7]
History of meningococcal disease [+9]